drugset
drugset / Trial / NCT00109993

Campath-1H + FK506 and Methylprednisolone for GVHD

NCT00109993 ↗

Phase 2 Completed 34 enrolled Case Comprehensive Cancer Center National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelSupportive care

Summary

RATIONALE: Alemtuzumab, tacrolimus, and methylprednisolone may be an effective treatment for graft-versus-host disease caused by a donor stem cell transplant. PURPOSE: This phase II trial is studying how well giving alemtuzumab together with tacrolimus and methylprednisolone works in treating acute graft-versus-host disease in patients who have undergone donor stem cell transplant.

Timeline

Start
2005-01
Primary completion
2006-06
Completion
2007-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Alemtuzumab Monoclonal antibody — Intravenous
Background Methylprednisolone Other / unclassified — Intravenous
Background Tacrolimus Small molecule — Intravenous

Indications

breast cancer gestational trophoblastic neoplasm graft versus host disease leukemia myelodysplastic syndrome myelodysplastic/myeloproliferative disease myeloproliferative neoplasm neuroblastoma ovarian cancer plasma cell neoplasm testicular germ cell tumor